AzTrials
AzTrials

AKI - Acute Kidney InjuryNCT06564376

Tailored MgSO4 Supplementation to Reduce Complications in Pediatric Heart Surgery

A study testing total magnesium and ionized magnesium in people with AKI - Acute Kidney Injury and Arrythmia, run by West Virginia University at 1 site in United States.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record

Search all trials

Trial summary

Lay Summary This study tests two ways of measuring blood magnesium after heart surgery. Children who need heart surgery may have heart and kidney problems after surgery. The right amount of magnesium in blood reduces this risk. This study will test the best way to measure magnesium. Read more about this study

Who is it for?
Ages 0 to 18 years
What is being tested?
total magnesium and ionized magnesium
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
96 participants
Where
1 siteUnited States
Study dates
1 Aug 2026to Jun 2029
Phase
Interventional

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 0 to 18 years
  • All sexes
  • No healthy volunteers
  • Child, Adult

Who may be able to join

  • Children undergoing cardiac surgery utilizing cardiopulmonary bypass

Who cannot join

  • Children undergoing cardiac surgery without cardiopulmonary bypass
  • Children with Renal disease
  • Children with pre-existing arrhythmia
  • Children on anti-arrhythmia medication

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Frank L Casey, MD contact

3042931017

flcasey@hsc.wvu.edu

United States1 site
  • West Virginia University

    Morgantown, West Virginia, 26506

Other trials in United States

About this study

Official title: Individually Tailored MgSo4 Supplementation to Reduce Cardiac and Renal Complications in Pediatric Heart Surgery

Lay Summary

This study tests two ways of measuring blood magnesium after heart surgery. Children who need heart surgery may have heart and kidney problems after surgery. The right amount of magnesium in blood reduces this risk. This study will test the best way to measure magnesium. This will let doctors choose the right dose of MgSO4. MgSO4 is a magnesium supplement. Taking MgSO4 after heart surgery helps children. For each child, it is best to personalize MgSO4 dose. This is based on the amount of magnesium in blood. This study will test two ways of personalizing MgSO4 dose.

Read more

In the blood, there are two kinds of magnesium. Usually, blood magnesium tests measure both forms together. This does not say anything about active magnesium. This study will measure the two forms separately. Then, MgSO4 will be given based on either the active or whole magnesium. Measuring active magnesium is good. Active magnesium levels change faster than total. That means active magnesium tests may better protect children. Also, active magnesium has more of an impact on heart and kidney function. Focusing on the active form will help these organs stay healthy.

To test how well the MgSO4 is working, heart and kidneys will be examined. After surgery, certain harmful heart rhythms can occur. The types and number of harmful rhythms will be studied. Kidney problems can also happen after heart surgery. Kidney health will be studied. To help understand how active magnesium works, further tests will be done. These tests will look for evidence of poor health in the cells that make up the heart, kidney, and blood.

Read the detailed description

Hypothesis: Modulating patient Mg levels based on ionized Mg will have clinical and functional benefits over using total Mg, due to the increased sensitivity and specificity of the ionized form. The primary goal of this project is to experimentally test the benefit of maintaining ionized normomagnesemia after cardiac surgery in children with regard to renal function and arrhythmia incidence . A secondary goal is to develop a model for predicting AKI after cardiac surgery in children, using a machine learning approach to understand interrelationships between magnesium-dependent physiological processes (Figure 1B). Successful completion of this project will define the utility and positionality of ionized Mg as an actor in pediatric post-surgical AKI, and its synergy with established clinical and physiological outcomes.

Aim 1: Investigating use of ionized Mg for Mg repletion therapy

In this aim, patients will be randomized to one of two strategies for Mg repletion therapy, one utilizing ionized Mg, the other using total Mg. The effects of these two strategies on clinical and physiological outcomes will be measured, as will the durability of the different Mg repletion strategies in preventing or correcting hypomagnesemia. 96 participants will be enrolled in this study. Because arrhythmia risk and AKI risk are dramatically stratified by age, subjects will be age-matched into the following groups: 0-1 month, 2 months to 2 years, 3- 9 years, 9 years -18 years. Children will be randomly assigned to one of two Mg repletion strategies. Randomization will occur after consenting and reaffirmation that the child/family/guardian still continue to agree to participate in the study. For each age group there will be 24 sealed envelopes that identify which treatment strategy for magnesium repletion they will be assigned (Total or ionized). This envelope will be opened at SBAR prior to the induction of anesthesia. Magnesium levels will be drawn and sent as per standard protocol. All patients will have ionized magnesium levels obtained with every blood gas, but only those in the ionized group will the physicians see and treat the magnesium based upon that value. Patients with hypomagnesemia ( value less than or equal to 1.8 Mg/dl in the total Magnesium group will be given MgSO4 at a standard dose of 50 mg/kg over 1 hour beginning at the intraoperative stage and at every subsequent timepoint where an individual's lab values show hypomagnesemia (Table 1). Those patients in the ionized magnesium group will be dosed according to Table 1 beginning at the intraoperative stage and at every subsequent timepoint where an individual's lab values show hypomagnesemia (Table 1). Study participants will be blinded to treatment group. Researchers will not be blinded at the time of MgSO4 administration due to logistical pharmacy requirements. All data analysis including ECG analysis will be performed by blinded researchers. In one arm, Mg repletion will be titrated using ionized Mg as a measure, maintaining an ionized Mg level of 0.98-1.46 mg/dl. In the other, Mg repletion will be titrated using total Mg as a measure. Due to reagents used by WVU labs, the reference range for total Mg is 1.9-3.1 mg/dL; patients in the total Mg arm will be maintained in this range. To ensure proper electrolyte balance, Ca2+, K+, and Na+ will be maintained within appropriate ranges using standard methodology.

Mg level will be measured on all arterial blood gases. Mg will be measured at least: pre-incision, at the completion of the procedure, and twice a day for 48 hours after surgery. In order to assess differences in post-treatment Mg maintenance after cessation of therapy, ionized and total Mg levels will also be measured 4 hours after Mg supplementation.

Urinary NGAL and Creatinine will be measured pre-bypass, 2 hours after bypass and 24 hours after bypass to assess for renal injury.

Clinical outcomes to be measured include:

  1. Urine output, measured hourly for 48 hours after surgery.
  2. Blood lactate, measured at least daily (standard of care).
  3. Time to extubation.
  4. Occurrence of non-sinus cardiac rhythms, with special attention given to accelerated junctional rhythms.

Magnesium dosing Total Mg (mg/dL) Less than or equal to 1.8 MgSO4 dose 50 mg/kg Ionized Mg Observed Mg(Mg/dL) MgSO4 dose 1.3 10 mg/kg - 1 hr 1.2 20 mg/kg - 1 hr 1.0 30 mg/kg - 1 hr 0.9 40 mg/kg - 1 hr 0.8 50 mg/kg - 1hr

Being tested
total magnesium, ionized magnesium
Keywords
Acute Kidney Injury, Arrhythmias, Congenital heart surgery, Cardiopulmonary bypass
Medical subject headings
Acute Kidney Injury, Arrhythmias, Cardiac, Heart Defects, Congenital

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • total magnesiumDiagnostic test

    Treatment based on total Magnesium

  • ionized magnesiumDevice

    Treatment based on ionized magnesium

Study groups in NCT06564376
Study groupRoleWhat they receive
Total magnesiumOtherMagnesium dosing based on total Mg blood level
Receives: Diagnostic Test: total magnesium
ionized MagnesiumActive comparatorMagnesium dosing based upon ionized Mg level
Receives: Device: ionized magnesium

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Duration from reanimation to sinus rhythm

    Measured: 48 hours after reanimation

  2. Time in non-sinus rhythms: within 24h of removing aortic cross-clamp

    Measured: first 24 hours after reanimation

  3. Time in non-sinus rhythms: 24-48h after removing aortic cross-clamp

    Measured: 24-48 hours after reanimation

  4. Presence of any arrhythmia

    Defined as any non-sinus rhythm

    Measured: 48 hours after reanimation

  5. Urine NGAL concentration

    Sensitive marker of acute kidney injury

    Measured: 48 hours after reanimation

  6. Urine Creatinine concentration

    The combination of NGAL/Creatine increases sensitivity marker of acute kidney injury

    Measured: 48 hours after reanimation

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted21 Aug 2024
  2. Study start1 Aug 2026 (estimated)
  3. Primary completionDec 2028 (estimated)
  4. Study completionJun 2029 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Parallel groups
Masking
Triple blind
Who is masked
Participant, Investigator, Outcomes assessor
Enrolment
96 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06564376
Sponsor's protocol ID
2310861427
Status last verified
Jun 2026
First submitted
19 Aug 2024
Last updated
16 Jun 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in